Core Insights - BillionToOne, Inc. reported significant financial growth in Q4 2025 and raised its revenue guidance for 2026, reflecting strong demand for its molecular diagnostics products [1][4]. Financial Highlights - Total revenue for Q4 2025 was $96.1 million, a 113% increase from $45.1 million in Q4 2024 [5][7]. - Prenatal testing revenue reached $86.1 million in Q4 2025, up 99% from $43.2 million in Q4 2024 [5][11]. - Oncology testing revenue surged to $9.1 million in Q4 2025, an increase of 735% from $1.1 million in Q4 2024 [5][11]. - Gross profit margin improved to 71% in Q4 2025, compared to 57% in Q4 2024, driven by higher average selling prices (ASP) and reduced costs [8][12]. - Operating income was $10.3 million in Q4 2025, reversing an operating loss of $11.7 million in Q4 2024 [9][10]. Recent Operating Highlights - The company delivered 170,000 tests in Q4 2025, a 47% increase from 116,000 tests in Q4 2024 [5][6]. - BillionToOne launched new prenatal and oncology products in early 2026, including non-invasive prenatal tests for fetal antigen status and expanded applications for its Northstar platform [5][14]. - The company expects full-year 2026 revenue to be between $430 million and $445 million, representing a growth of 41% to 46% compared to 2025 [14]. Full Year 2025 Financial Results - Total revenue for 2025 was $305.1 million, a 100% increase from $152.6 million in 2024 [11][12]. - Gross profit for 2025 was $208.5 million, with a gross margin of 68%, up from 53% in 2024 [12][13]. - Net income available to common shareholders for 2025 was $2.9 million, or $0.14 per diluted share, compared to a net loss of $41.6 million in 2024 [13]. Cash Position - As of December 31, 2025, BillionToOne held approximately $496.0 million in cash and cash equivalents, indicating a strong liquidity position [13][22].